Respiratory medicine has been a major success story for the UK pharmaceuticals sector. In this report we provide an update on the current market dynamics in asthma and COPD, and on four key product development companies in our small & midcap universe: Skyepharma, Synairgen, Vectura and Verona Pharma. The unmet need in respiratory disease remains high, and with significant market changes expected in 2016 and beyond we believe that the subsector offers rich investment opportunities across generics ....

28 Jan 2016
A very attractive subsector in a year of change

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A very attractive subsector in a year of change
SkyePharma (SKP:LON), 0 | Synairgen plc (SNG:LON), 7.9
- Published:
28 Jan 2016 -
Author:
N+1 Singer Team -
Pages:
34 -
Respiratory medicine has been a major success story for the UK pharmaceuticals sector. In this report we provide an update on the current market dynamics in asthma and COPD, and on four key product development companies in our small & midcap universe: Skyepharma, Synairgen, Vectura and Verona Pharma. The unmet need in respiratory disease remains high, and with significant market changes expected in 2016 and beyond we believe that the subsector offers rich investment opportunities across generics ....